论文部分内容阅读
目的了解宫颈腺癌治疗患者生存预后的影响因素,为预防和治疗宫颈腺癌提供依据。方法选取2008—2013年6月在浙江省肿瘤医院接受治疗的211例宫颈腺癌患者,根据病例资料和随访情况,估计生存率并分析其影响因素。结果 211例宫颈腺癌治疗患者随访10~81个月,中位数为49个月。43例患者因宫颈腺癌死亡,占20.38%。宫颈腺癌1年生存率为96.2%,3年生存率为88.6%,5年生存率为74.7%。多因素Cox分析显示,年龄(RR=4.940,95%CI:1.925~12.678)、盆腔淋巴结转移(RR=2.391,95%CI:1.311~4.360)和腹主动脉旁淋巴结转移(RR=6.344,95%CI:1.007~39.990)、FIGO分期(与I期相比,Ⅲ期:RR=5.315,95%CI:2.760~12.203;Ⅳ期:RR=9.932,95%CI:2.905~18.846)是宫颈腺癌患者生存的独立危险因素。结论宫颈腺癌患者的年龄、FIGO分期、盆腔淋巴结转移及腹主动脉旁淋巴结转移是影响宫颈腺癌患者生存的危险因素。
Objective To investigate the influencing factors of survival and prognosis of patients with cervical adenocarcinoma and provide basis for prevention and treatment of cervical adenocarcinoma. Methods A total of 211 cervical adenocarcinoma patients who were treated in Zhejiang Cancer Hospital from June 2008 to June 2013 were selected. The survival rate was estimated and the influencing factors were analyzed according to the case data and follow-up. Results 211 cases of patients with cervical adenocarcinoma were followed up for 10 to 81 months, the median was 49 months. 43 patients died of cervical adenocarcinoma, accounting for 20.38%. The 1-year survival rate of cervical adenocarcinoma was 96.2%, the 3-year survival rate was 88.6%, and the 5-year survival rate was 74.7%. Multivariate Cox analysis showed that age (RR = 4.940, 95% CI 1.925 to 12.678), pelvic lymph node metastasis (RR = 2.391, 95% CI 1.311 to 4.360) and paraaortic lymph node metastasis % CI: 1.007-39.990), FIGO staging (stage III: RR = 5.315,95% CI: 2.760-12.203 compared with stage I; stage IV: RR = 9.932,95% CI: 2.905-18.846) Cancer patients with independent risk factors for survival. Conclusion Age, FIGO staging, pelvic lymph node metastasis and para-aortic lymph node metastasis of cervical adenocarcinoma are the risk factors affecting the survival of patients with cervical adenocarcinoma.